Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6591MR)

This product GTTS-WQ6591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6591MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ363MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ9696MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ15900MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ6998MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ2300MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ6143MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ2076MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW